Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
DIABETOLOGY & METABOLIC SYNDROME, cilt.10, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 10
- Basım Tarihi: 2018
- Doi Numarası: 10.1186/s13098-018-0331-8
- Dergi Adı: DIABETOLOGY & METABOLIC SYNDROME
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Anahtar Kelimeler: Type 2 diabetes, Gliclazide, Glycemic control, Tolerability, Real-world, CARDIOVASCULAR OUTCOMES, RAMADAN, HYPOGLYCEMIA, EMPAGLIFLOZIN, SULFONYLUREA, SAXAGLIPTIN, SITAGLIPTIN, MORTALITY
- İstanbul Üniversitesi Adresli: Evet
Özet
Background: Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment.